Avidity Biosciences Inc’s filing revealed that its Chief Medical Officer Hughes Steven George unloaded Company’s shares for reported $0.3 million on Mar 20 ’25. In the deal valued at $31.06 per share,9,578 shares were sold. As a result of this transaction, Hughes Steven George now holds 72,850 shares worth roughly $2.43 million.
Then, Boyce Sarah sold 31,540 shares, generating $979,563 in total proceeds. Upon selling the shares at $31.06, the President and CEO now owns 305,871 shares.
Before that, Flanagan W. Michael sold 11,780 shares. Avidity Biosciences Inc shares valued at $365,868 were divested by the Chief Scientific Officer at a price of $31.06 per share. As a result of the transaction, Flanagan W. Michael now holds 80,195 shares, worth roughly $2.67 million.
Citigroup initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on March 13, 2025; the price target was $70. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Scotiabank began covering RNA with “Sector outperform” recommendation on March 07, 2025. H.C. Wainwright started covering the stock on December 20, 2024. It rated RNA as “a Buy”.
Price Performance Review of RNA
On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock jump 7.98% to $33.30. Over the last five days, the stock has lost -1.57%. Avidity Biosciences Inc shares have risen nearly 14.51% since the year began. Nevertheless, the stocks have risen 37.38% over the past one year. While a 52-week high of $56.00 was reached on 03/13/25, a 52-week low of $21.56 was recorded on 01/14/25. SMA at 50 days reached $31.14, while 200 days put it at $38.86.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 31.61, which if violated will result in even more drops to 29.92. On the upside, there is a resistance level at 34.39. A further resistance level may holdings at 35.48. The Relative Strength Index (RSI) on the 14-day chart is 56.39, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.47, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 39.95%. Stochastics %K at 44.37% indicates the stock is a holding.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-02-28, growing by 2.0 million shares to a total of 16.95 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 14.95 million shares. There was a rise of 11.82%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 26, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $67 price target.
